Stock RVMD REVOLUTION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
37.95 USD -0.47% Intraday chart for Revolution Medicines, Inc. -3.70% +32.32%
May. 09 Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating MT
May. 08 Revolution Medicines Q1 Net Loss Narrows MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating
MT
Revolution Medicines Q1 Net Loss Narrows
MT
Revolution Medicines : RVMD Corporate Presentation
PU
Transcript : Revolution Medicines, Inc., Q1 2024 Earnings Call, May 08, 2024
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
AQ
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
Revolution Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
AQ
Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating
MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating
MT
North American Morning Briefing : Stock Futures -2-
DJ
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs
AQ
Revolution Medicines to Participate in Upcoming Investor Conferences
AQ
Aethon Therapeutics, Inc. Announces Collaboration with Revolution Medicines, Inc. to Discover and Develop Novel Aethon Antibody Programs
CI
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
AQ
Revolution Medicines Insider Sold Shares Worth $805,652, According to a Recent SEC Filing
MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target
MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVMD Stock
  4. News Revolution Medicines, Inc.